Goldstein, Felicia C.

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer’s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.

Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 130

Impaired fear conditioning in Alzheimer’s disease

Hamann, S., Monarch, E. S., & Goldstein, F. C. (2002) · Neuropsychologia

Memory and Neural MechanismsDementia and Cognitive Impairment Research

Cited by 129

Expanded Demographic Norms for Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set

Sachs, B. C., Steenland, K., Zhao, L., Hughes, T. M., Weintraub, S., Dodge, H. H., Barnes, L. L., Craft, S., Parker, M. L., & Goldstein, F. C. (2020) · Alzheimer Disease & Associated Disorders

Dementia and Cognitive Impairment ResearchHistorical and Modern Theater Studies

Cited by 66

Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores

Dodge, H. H., Goldstein, F. C., Wakim, N. I., Gefen, T., Teylan, M., Chan, K. C. G., Kukull, W. A., Barnes, L. L., Giordani, B., Hughes, T. M., et al. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Dementia and Cognitive Impairment ResearchPsychological Testing and Assessment

Cited by 54